A5074934110- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Lung Cancer Research Studies
- Immune cells in cancer
- Lung Cancer Diagnosis and Treatment
- Cytokine Signaling Pathways and Interactions
- Epigenetics and DNA Methylation
- CAR-T cell therapy research
- Colorectal Cancer Surgical Treatments
- Nanoplatforms for cancer theranostics
- Cancer Mechanisms and Therapy
- Cancer, Stress, Anesthesia, and Immune Response
- RNA modifications and cancer
- Cancer, Hypoxia, and Metabolism
- Immune Cell Function and Interaction
- Metastasis and carcinoma case studies
- Autophagy in Disease and Therapy
- Cancer Research and Treatments
- Colorectal and Anal Carcinomas
- Inflammatory Biomarkers in Disease Prognosis
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer Diagnosis and Treatment
- Breast Cancer Treatment Studies
The University of Texas MD Anderson Cancer Center
2020-2024
Shandong Tumor Hospital
2016-2024
Shandong First Medical University
2016-2024
Academy of Medical Sciences
2022-2023
Affiliated Hospital of Southwest Medical University
2023
Shandong University
2016-2022
China University of Geosciences
2021
Chongqing University
2019
University of Jinan
2016-2018
Abstract Diverse factors contribute to the limited clinical response radiotherapy (RT) and immunotherapy in metastatic non–small cell lung cancer (NSCLC), among which is ability of these tumors recruit a retinue suppressive immune cells—such as M2 tumor-associated macrophages (TAM)—thereby establishing an immunosuppressive tumor microenvironment that contributes progression radio resistance. TAMs are activated by STAT6 signaling pathway. Therefore, we targeted using antisense oligonucleotide...
Tumors deploy various immune-evasion mechanisms that create a suppressive environment and render effector T-cells exhausted inactive. Therefore, rational utilization of checkpoint inhibitors may alleviate exhaustion partially restore antitumor functions. However, in high-tumor-burden models, the blockade fails to maintain optimal efficacy, other interventions are necessary overcome inhibitory tumor stroma. One such strategy is use radiotherapy reset microenvironment maximize systemic...
While improvements in immunoradiotherapy have significantly improved outcomes for cancer patients, this treatment approach has nevertheless proven ineffective at controlling the majority of malignancies. One mechanisms resistance to is that immune cells may be suppressed via myriad different checkpoint receptors. Therefore, simultaneous blockade multiple receptors enhance efficacy immunoradiotherapy.We combined NBTXR3-enhanced localized radiation with three receptors: PD1, LAG3, and TIGIT,...
Epidermal growth factor receptor (EGFR) is over-expressed in about 50% of Triple negative breast cancers (TNBCs), but EGFR inhibitors have not been effective treating TNBC patients. Increasing evidence supports that autophagy was related to drug resistance at present. However, the role and mechanism treatment remain unknown. In current study, we investigated effect inhibitor gefitinib (Ge) cells vitro nude mice vivo. Our study demonstrated inhibition by 3-Methyladenine or bafilomycin A1...
Abstract Background Combining radiotherapy with PD1 blockade has had impressive antitumor effects in preclinical models of metastatic lung cancer, although anti-PD1 resistance remains problematic. Here, we report results from a triple-combination therapy which NBTXR3, clinically approved nanoparticle radioenhancer, is combined high-dose radiation (HDXRT) to primary tumor plus low-dose (LDXRT) secondary along checkpoint mouse model anti-PD1-resistant cancer. Methods Mice were inoculated...
Aim: We aimed to evaluate the prognostic values of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR), lymphocyte-to-monocyte (LMR) and systemic immune-inflammation index (SII) in patients with brain metastases from non-small-cell lung cancer (NSCLC). Materials & methods: conducted Kaplan–Meier analysis multivariable Cox NLR, PLR, LMR SII. Results: showed that low LMR, high PLR SII groups were associated shorter overall survival. Multivariable revealed independent factors for...
Aim: To evaluate the value of pretreatment blood biomarkers in predicting pathologic responses to neoadjuvant chemoradiotherapy (neo-CRT) patients with locally advanced rectal cancer. Materials & methods: We conducted logistic regression analysis and receiver operating characteristic assess predictive biomarkers. The outcome was defined by complete response good response. Results: Carcinoembryonic antigen (CEA) (p < 0.001), neutrophil-to-lymphocyte ratio = 0.024), platelet-to-lymphocyte...
Radiotherapy (XRT), a well-known activator of the inflammasome and immune priming, is in part capable reversing resistance to anti-PD1 treatment. The NLRP3 pattern recognition receptor which activated by both exogenous endogenous stimuli, leading downstream inflammatory response. Although typically recognized for its role exacerbating XRT-induced tissue damage, can also yield an effective antitumor response when used proper dosing sequencing with XRT. However, whether agonist boosts...
Radiotherapy (RT) has been used to control tumors by physically damaging DNA and inducing apoptosis; it also promotes antitumor immune responses via neoantigens release augmenting immune-oncology agents elicit systemic response. Tumor regression after RT can recruit inflammatory cells, such as tumor-associated macrophages CD11b+ myeloid cell populations, a major subset of which may actually be immunosuppressive. However, these cells express Toll-like receptors (TLRs) that stimulated reverse...
Introduction Effective infiltration of chimeric antigen receptor T (CAR-T) cells into solid tumors is critical for achieving a robust antitumor response and improving therapeutic outcomes. While CAR-T cell therapies have succeeded in hematologic malignancies, their efficacy remains limited due to poor tumor penetration an immunosuppressive microenvironment. This study aimed evaluate the potential low-dose radiotherapy (LDRT) administered before T-cell therapy enhance effect by promoting...
Lymphatic vessel invasion (LVI) is promising in determining prognosis and treatment strategies, but the application of LVI as a histopathological criterion breast cancer patients especially those different subgroups controversial. This research aims to evaluate prognostic value assessed by D2-40 not only with early invasive also lymph node-negative, node-positive, luminal A-like, B-like, HER2-enriched, triple-negative subgroups. The study cohort included 255 median follow-up 101 months....
Triple-negative breast cancer (TNBC) is a particular subtype of malignant tumor with poorer prognosis than other molecular subtypes. Previous studies have demonstrated that some abnormal expression non-coding RNAs including microRNAs (miRNAs) and long (lncRNAs) were closely related to cell proliferation, apoptosis, invasion, migration drug sensitivity. However, the role in pathogenesis TNBC still unclear. In order characterize mechanism TNBC, we downloaded RNA data miRNA from genome atlas...
Radiation therapy (RT) is emerging as an interventional modality in the cancer-immunity cycle, augmenting activation of adaptive immune response against tumors. RT, particularly combination with immunotherapy, can enhance memory effects and shape tumor-directed T-cell populations. However, a single cycle RT delivered to limited number polymetastatic lesions rarely sufficient achieve systemic control. We hypothesize that several rounds akin immunotherapeutic drugs, likely provide greater...
Chemo-radiotherapy (CRT) remains the main treatment modality for non-small-cell lung cancer (NSCLC). However, its clinical efficacy is largely limited by individual variations in radio-sensitivity and radiotherapy-associated toxicity. There an urgent need to identify genetic determinants that can explain patients' likelihood develop recurrence toxicity following CRT. In this study, we performed comprehensive genomic profiling, using a 474-cancer- radiotherapy-related gene panel, on...
Abstract Background Combining interleukin-2 (IL-2) with radiotherapy (RT) and immune checkpoint blockade (ICB) has emerged as a promising approach to address ICB resistance. However, conventional IL-2 cytokine therapy faces constraints owing its brief half-life adverse effects. RDB 1462, the mouse ortholog of Nemvaleukin alfa, is an engineered intermediate affinity that selectively stimulates antitumor CD8 T NK cells while limiting regulatory cell expansion. This study aimed evaluate...
Radiation therapy (XRT) has a well-established role in cancer treatment. Given the encouraging results on immunostimulatory effects, radiation been increasingly used with immune-check-point inhibitors metastatic disease, especially when immunotherapy fails due to tumor immune evasion. We hypothesized that using high-dose stereotactic cycles (pulses) would increase T-cell priming and repertoire each pulse build memory an incremental manner. To prove this hypothesis, we studied combination of...